news
September 2026
Notice of Award - AFIRM-002; $3.5M DoW Contract
“On behalf of the AFIRM Coordinating Center, we wish to congratulate you being approved for inclusion in the MTEC AFIRM-004 program.”
February 2026
Selected to negotiate $3.5 million government contract
“On behalf of the AFIRM Coordinating Site Management Office (CSMO), we wish to congratulate you for being recommended by the Defense Health Agency Research and Engineering Directorate for negotiation under the AFIRM 002 FY25 solicitation.”
August 2021
We are thrilled to announce that Diadem Biotherapeutics has been selected as the winner and recipient of the first Amgen Golden Ticket Award at BioLabs LA!
Awarded 1st AMGEN Golden Ticket
With lead investment from Novateur Ventures, Diadem Biotherapeutics raised $1.2 million to develop first- and best-in class immunotherapies, bringing us one step closer to developing cures for patients worldwide.
Raised $1.2 million
July 2021
May 2021
Diadem Biotherapeutics is officially a Creative Destruction Lab graduate, successfully completing nine months of objective based startup mentorship!
Creative Destruction Lab
November 2019
IndieBio Batch 9
Diadem Biotherapeutics is thrilled to join the world’s leading biotechnology startup accelerator program IndieBio in San Francisco, CA!
September 2019
Diadem Biotherapeutics is honored to have been selected to pitch at the 2019 QB3 Biotech/Biopharma Pitch Summit!